Wednesday, May 6
CVS blowout beat and Moderna flu trial win headline the session
Two of your most pressured names just delivered the kind of results that change the conversation, and a third may have quietly cracked open a new market.
Top Stories
Moderna's mRNA flu vaccine beats conventional shots in 40,000-person trial
In a head-to-head late-stage trial of adults 50 and older, MRNA's mRNA-based flu vaccine demonstrated superior efficacy over traditional flu shots, a result that clears one of the most important de-risking hurdles in the company's post-COVID pipeline. The flu vaccine market is enormous, and a commercial approval would open a major new revenue stream while proving that mRNA technology can displace entrenched vaccine categories. Watch for regulatory filing timelines and any guidance update from management on commercialization costs, as those will determine how quickly this translates from trial win to revenue reality.
CVS and Kraft Heinz both beat estimates, both raise the turnaround case
CVS posted Q1 revenues of $100.43B and EPS of $2.57 against a $2.21 consensus, raised full-year 2026 guidance, and showed improved medical cost controls across Aetna and its other segments, directly addressing the concerns that have weighed on the stock for years. Kraft Heinz reported Q1 EPS of $0.58 on sales of $6.047B, both above estimates, with CEO Steve Cahillane's strategy showing early traction in the U.S. market. Two beaten-down names delivering credible beats on the same day is not coincidence to dismiss - the raised guidance from CVS and the U.S. momentum at KHC are forward-looking signals that their respective turnarounds may be gaining real structural footing.
Flutter loses its FanDuel CEO as Snap and WBD each bury a bright spot
Flutter's U.S. FanDuel CEO Amy Howe departed after five years, replaced by President Christian Genetski, a leadership shake-up at FLUT's most critical growth asset that introduces uncertainty at a competitive moment for U.S. sports betting market share. Snap beat Q1 revenue and EPS estimates with 12% revenue growth and returning DAU growth, but terminated its $400M AI deal with Perplexity and issued cautious guidance citing Middle East geopolitical uncertainty, muddying what was otherwise an operational improvement story. Warner Bros. Discovery's $2.92B net loss is largely a technical result driven by a $2.8B termination fee from the failed Paramount Skydance bid, and the more meaningful number is streaming revenue beating expectations on HBO Max global expansion - the real risk at WBD remains its debt load, not this quarter's headline figure.
Also Today
- • JPM's Kinexys completes first real-time tokenized Treasury cross-border redemption
- • Samsung hits $1 trillion valuation on AI memory chip demand surge
- • Eli Lilly adds $4.5B Indiana plant, state commitment now tops $21B
Takeaway
Today's session rewards patience in beaten-down names, but leadership instability and macro caution are real enough to keep position sizing honest.
